S&N Defies CMS History, Secures Coverage After Negative Proposed Decision
This article was originally published in The Gray Sheet
Executive Summary
Smith & Nephew's last-ditch effort to supply CMS with pooled data from a PMA study convinced the agency to overturn its proposed national non-coverage decision for ultrasound stimulation for nonunion fracture healing
You may also be interested in...
CMS Proposes Non-Coverage For S&N Exogen For Nonunion Fracture Healing
CMS is continuing its recent trend of promoting clinical trial coverage by proposing to extend reimbursement for Smith & Nephew's Exogen ultrasound bone growth stimulator for nonunion fracture healing for recipients enrolled in a qualifying trial
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.